KUALA LUMPUR, Dec 2 (Bernama) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (4TEEN4) to manufacture and commercialise Procizumab.
The first-in-class monoclonal antibody Procizumab offers a new approach for the treatment of life-threatening diseases related to acute circulatory failure.
Under terms of the agreement, the companies will collaborate to transfer and optimise the manufacturing process for Procizumab, according to a statement.
AGC Biologics will manufacture the clinical trial materials at its site in Chiba and transfer to its Copenhagen facility for all late phase activities including commercialisation, to support early and late clinical phases and launch readiness of 4TEEN4’s monoclonal antibody.
“We look forward to partnering with 4TEEN4 and working together to develop and manufacture this revolutionary treatment, and help it reach the critical clinical trial phase,” said Patricio Massera, Chief Executive Officer at AGC Biologics.
“Our Chiba and Copenhagen sites have the proven experience and expertise to help 4TEEN4 in its journey towards the clinical and market supply of this new innovative therapy.”
4TEEN4 is a preclinical-stage biotech company dedicated to helping critically-ill patients suffering from loss of heart function and circulatory shock.
Its flagship biologic, Procizumab, is a humanised monoclonal antibody able to inhibit the activity of its target, Dipeptidyl Peptidase 3 (DPP3), stabilise cardiovascular function and potentially increase survival chances e.g., in cardiogenic and septic shock.
“AGC is a high-quality partner with global manufacturing expertise and extensive commercial supply experience, and we are pleased to start a long-standing relationship as we continue to progress in our clinical development,” said Andreas Bergmann, founder and CEO of 4TEEN4.
For more information, visit www.agcbio.com.
-- BERNAMA
No comments:
Post a Comment